title: The effects of oral micronized progesterone on smoked cocaine self-administration in women.
abstract: There are currently no FDA-approved pharmacotherapies for cocaine abuse. Converging preclinical and clinical evidence indicates that progesterone may have potential as a treatment for cocaine-abusing women, who represent a growing portion of cocaine users. We have previously shown that oral progesterone reduced the positive subjective effects of cocaine in female cocaine users during the follicular phase of the menstrual cycle, when endogenous progesterone levels were low. To extend these findings, the present study assessed the effects of oral progesterone (150 mg BID) administered during the follicular phase on smoked cocaine self-administration in women relative to the normal follicular and luteal phases. Healthy, non-treatment seeking female cocaine smokers (N=10) underwent three 4-day inpatient stays, during: 1) a normal follicular phase; 2) a normal luteal phase; and 3) a follicular phase when oral progesterone was administered. During each stay, participants completed 4 self-administration sessions in which they first smoked a "sample" dose of cocaine (0, 12, 25 or 50 mg) and then had 5 opportunities at 14-minute intervals to self-administer that dose at a cost of $5 per dose. Expected cocaine dose effects on self-administration, subjective effects, and cardiovascular effects were observed. However, there was no effect of oral progesterone administration or menstrual cycle phase on cocaine self-administration. Thus, oral progesterone was not effective in reducing cocaine use in women under the current conditions. However, based on previous literature, further research assessing the role of oral progesterone for the treatment of cocaine dependence in women is warranted.
authors.affiliation: Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA. sc2432@columbia.edu
authors.forename: Stephanie Collins
authors.initials: SC
authors.lastname: Reed
authors.forename: Suzette M
authors.initials: SM
authors.lastname: Evans
authors.forename: Gillinder
authors.initials: G
authors.lastname: Bedi
authors.forename: Eric
authors.initials: E
authors.lastname: Rubin
authors.forename: Richard W
authors.initials: RW
authors.lastname: Foltin
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000328:Adult; D003042:Cocaine / Q000008:administration & dosage*; D019970:Cocaine-Related Disorders / Q000097:blood / Q000188:drug therapy*; D004304:Dosage Forms; D004305:Dose-Response Relationship, Drug; D005260:Female; D006728:Hormones / Q000097:blood; D006801:Humans; D011374:Progesterone / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology*; D012646:Self Administration; D012907:Smoking
chemical_list: D004304:Dosage Forms; D006728:Hormones; D011374:Progesterone; D003042:Cocaine